# GRAIL

reported full NHS-Galleri trial results at the 2026 ASCO Annual Meeting showing a substantial reduction in stage IV cancer diagnoses and a four-fold higher cancer detection rate, presented Pathfinder 2 results from more than 35,000 participants, and has submitted an FDA PMA application for Galleri.

Source: https://en.bioecon.ru/companies/grail/
Updated: 2026-07-20

- Country: United States
- Ticker: GRAL

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Funding | $110 million equity financing with Samsung C&T and Samsung Electronics completed in June 2026 (2026-06-30) | https://grail.com/press-releases/grail-reports-second-quarter-2026-financial-results/ |
| Capacity | infrastructure capable of meeting demand of up to one million tests per year (2026-01-01) | https://investors.grail.com/node/8391/html |
| Certification | Clinical Laboratory Improvement Amendments of 1988 (CLIA) and College of American Pathologists (CAP) accredited clinical laboratory (2026-05-30) | https://grail.com/press-releases/grail-reports-full-results-from-nhs-galleri-trial-demonstrating-substantial-reduction-in-stage-iv-cancer-diagnoses-at-2026-asco-annual-meeting/ |
| Regulatory approval | Galleri test has not been cleared or approved by the U.S. FDA, with an advisory committee anticipated in the fall of 2026 (2026-08-05) | https://grail.com/press-releases/grail-reports-second-quarter-2026-financial-results/ |
| Production site | CLIA-certified laboratory located in Research Triangle Park, North Carolina (2024-08-14) | https://www.fiercebiotech.com/medtech/flying-solo-grail-will-cut-30-staff-and-narrow-its-rd-commercial-focus |
| Revenue | $44.7 million in total revenue for the second quarter of 2026 (2026-06-30) | https://grail.com/press-releases/grail-reports-second-quarter-2026-financial-results/ |

Independent sources: fiercebiotech.com

## Technologies

- [Multi-cancer early detection (MCED)](https://en.bioecon.ru/technology/multi-cancer-early-detection/)